RACHEL WARBURTON: Open Payments
NPI 1083133300 · COLUMBUS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,632 in 172 payments from 19 companies in 2025. Trend: 2023 $14 · 2024 $115 · 2025 $3,632
Food & beverage: $3,632
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 50 | $752 |
| Madrigal Pharmaceuticals | 13 | $388 |
| Ipsen Biopharmaceuticals, Inc | 10 | $384 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 18 | $299 |
| Janssen Scientific Affairs, LLC | 8 | $291 |
| Lilly USA, LLC | 11 | $274 |
| GENZYME CORPORATION | 9 | $175 |
| PFIZER INC. | 12 | $174 |
| Novo Nordisk Inc | 4 | $173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $152 |
Products named: TREMFYA, REZDIFFRA, XIFAXAN, IQIRVO, OMVOH, DUPIXENT, RINVOQ, Wegovy.
Industry payments across GA — which companies pay providers there.
